News
Avicenna Alliance is honoured to welcome Alfasigma as a new member!
Privately owned, Alfasigma is one of the leading Italian pharmaceutical companies, present in over 90 countries, through distributors and subsidiaries and has a workforce of around 3,000 people, R&D laboratories, and 5 production plants.
EU-funded project successfully develops AI software that grows and treats cancerous tumors
The Horizon Europe 2020 project EVO-NANO (Evolvable platform for programmable nanoparticle-based cancer therapies) has published the results of their recent research. The researchers, coming from seven different institutions, developed a platform that grows and treats virtual tumors using artificial intelligence (AI).
In silico used to validate Omicron variant detection method!
The Joint Research Centre (JRC) has developed a new method to detect the Omicron variant of COVID-19, which differs in its nucleic acid sequence from previous COVID-19 variants. The significant changes in its sequence have caused some fear as to whether existing tests would be able to detect Omicron.
The priorities of the upcoming French Presidency of the Council of the European Union - what’s new for Avicenna?
The French Presidency of the Council of the European Union is due to start on 1 January. On 9 December, Emmanuel Macron gave a press conference highlighting some of the priorities for the presidency.
New Avicenna UK Insilico Regulatory Innovation Task Force
The Avicenna International Affairs Working Group adds a new task force to its structure.
Two Commission Regulations are updated with acknowledgement of in silico methods as alternatives to in vivo testing
Two Regulations were draft amended by DG SANTE to reflect new mentions of in silico methods as alternatives to in vivo testing. The Commission has published the following draft regulations:
